309 related articles for article (PubMed ID: 26663262)
1. Contact immunotherapy enhances the therapeutic effects of nivolumab in treating in-transit melanoma: Two cases reports.
Fujimura T; Furudate S; Kakizaki A; Kambayashi Y; Haga T; Hashimoto A; Aiba S
J Dermatol; 2016 Jun; 43(6):686-9. PubMed ID: 26663262
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy in melanoma.
Feld E; Mitchell TC
Immunotherapy; 2018 Aug; 10(11):987-998. PubMed ID: 30149766
[TBL] [Abstract][Full Text] [Related]
3. Topical immunotherapy with diphencyprone (DPCP) for in-transit and unresectable cutaneous melanoma lesions: an inaugural Canadian series.
Yeung C; Petrella TM; Wright FC; Abadir W; Look Hong NJ
Expert Rev Clin Immunol; 2017 Apr; 13(4):383-388. PubMed ID: 28121191
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment of multiple in-transit melanomas on the leg with intensity-modulated radiotherapy and immune checkpoint inhibitors: Report of two cases.
Fujimura T; Kambayashi Y; Furudate S; Hidaka T; Sato Y; Tanita K; Tono H; Tsukada A; Hashimoto A; Aiba S
J Dermatol; 2017 May; 44(5):592-595. PubMed ID: 27914096
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy in melanoma: Recent advances and future directions.
Franklin C; Livingstone E; Roesch A; Schilling B; Schadendorf D
Eur J Surg Oncol; 2017 Mar; 43(3):604-611. PubMed ID: 27769635
[TBL] [Abstract][Full Text] [Related]
6. Treatment of warts with contact allergens.
Word AP; Nezafati KA; Cruz PD
Dermatitis; 2015; 26(1):32-7. PubMed ID: 25581668
[TBL] [Abstract][Full Text] [Related]
7. Topical immunotherapy with diphencyprone for in transit and cutaneously metastatic melanoma.
Damian DL; Saw RP; Thompson JF
J Surg Oncol; 2014 Mar; 109(4):308-13. PubMed ID: 24522938
[TBL] [Abstract][Full Text] [Related]
8. [Not Available].
Pagès C; Baroudjian B; Lebbé C
Bull Cancer; 2016 Nov; 103 Suppl 1():S132-S137. PubMed ID: 28057176
[TBL] [Abstract][Full Text] [Related]
9. Nivolumab: Immunotherapy in Malignant Melanoma.
Bayless H; Schneider S
Clin J Oncol Nurs; 2015 Aug; 19(4):430-2. PubMed ID: 26207707
[TBL] [Abstract][Full Text] [Related]
10. Response of metastatic mucosal melanoma to immunotherapy: It can get worse before it gets better.
Atrash S; Makhoul I; Mizell JS; Hutchins L; Mahmoud F
J Oncol Pharm Pract; 2017 Apr; 23(3):215-219. PubMed ID: 26811403
[TBL] [Abstract][Full Text] [Related]
11. Subacute CNS Demyelination after Treatment with Nivolumab for Melanoma.
Maurice C; Schneider R; Kiehl TR; Bavi P; Roehrl MH; Mason WP; Hogg D
Cancer Immunol Res; 2015 Dec; 3(12):1299-302. PubMed ID: 26419960
[TBL] [Abstract][Full Text] [Related]
12. Update on immunotherapy in melanoma.
Green J; Ariyan C
Surg Oncol Clin N Am; 2015 Apr; 24(2):337-46. PubMed ID: 25769716
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.
Faghfuri E; Faramarzi MA; Nikfar S; Abdollahi M
Expert Rev Anticancer Ther; 2015; 15(9):981-93. PubMed ID: 26313415
[TBL] [Abstract][Full Text] [Related]
14. [How to choose the optimal therapy? New issues in the treatment of metastatic melanoma].
Oláh J; Gyulai R
Magy Onkol; 2016 Mar; 60(1):17-21. PubMed ID: 26934346
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab in melanoma.
Specenier P
Expert Rev Anticancer Ther; 2016 Dec; 16(12):1247-1261. PubMed ID: 27776441
[TBL] [Abstract][Full Text] [Related]
16. [Targeted therapies for melanoma].
Leiter U; Meier F; Garbe C
Hautarzt; 2014 Jul; 65(7):600-6. PubMed ID: 24962553
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy of melanoma: efficacy and mode of action.
Wieder T; Brenner E; Braumüller H; Röcken M
J Dtsch Dermatol Ges; 2016 Jan; 14(1):28-37. PubMed ID: 26713633
[TBL] [Abstract][Full Text] [Related]
18. [Immunotherapy in the treatment of advanced or metastatic melanoma: nivolumab from phase I studies to approvement by European Medicines Agency].
Queirolo P; Tanda ET
Recenti Prog Med; 2015 Dec; 106(12):608-17. PubMed ID: 26780070
[TBL] [Abstract][Full Text] [Related]
19. [Editorial].
Schilling B; Schadendorf D
J Dtsch Dermatol Ges; 2016 Jan; 14(1):1-2. PubMed ID: 26713629
[No Abstract] [Full Text] [Related]
20. [Not Available].
Mateus C; Libenciuc C; Robert C
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
